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ORIGINAL RESEARCH ARTICLE: CERVIX AND HPVReporting and Assessing the Quality of Diagnostic Accuracy
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Rosemary Zuna, MD,5 Miriam Cremer, MD, MPH,6 Colleen K. Stockdale, MD, MS,7
Mark H. Einstein, MD, MS,8 and Nicolas Wentzensen, MD, PhD, MS1Objective: We adapted the Quality Assessment of Diagnostic Accuracy
Studies 2 (QUADAS-2) tool for studies of cervical cancer screening and
management and used the adapted tool to evaluate the quality of studies in-
cluded in a systematic review supporting the 2019 Risk-Based Manage-
ment Consensus Guidelines.
Methods: We evaluated the quality of all studies included in our systematic
review for postcolposcopy (n = 5) and posttreatment (n = 23) surveillance using
QUADAS-2 criteria. Subsequently, we adapted signaling questions to indica-
tions of cervical cancer screening and management. An iterative process was
carried out to evaluate interrater agreement between 2 study authors (M.A.C.
andN.W.). Discrepant ratingswere discussed, and criteriawere adapted accord-
ingly.We also evaluated the influence of study quality on risk estimates and be-
tween study variation using stratified subgroup meta-analyses.
Results: Twelve signaling questions for bias assessment that were adapted to or
newly developed for cervical cancer screening and management are described
here. Interrater agreement on bias assessment increased from 70% to 83%during
the adaptation process. Detailed assessment of bias and applicability showed that
all studies on postcolposcopy management and 90% of studies on posttreatment
management had high risk of bias in at least 1 domain.Most commonly, high risk
of biaswas observed for the patient selection domain, indicating the heterogeneity
of study designs and clinical practice in reported studies.
Conclusions: The adapted QUADAS-2 will have broad application for
researchers, evidence evaluators, and journals who are interested in designing,
conducting, evaluating, and publishing studies for cervical cancer screening
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T he 2019 American Society of Colposcopy and Cervical Pa-thology (ASCCP) Risk-Based Management Consensus
Guidelines address management of patients with abnormal cervi-
cal cancer screening results and management of patients who are
under surveillance after colposcopy or treatment of cervical
precancers. Two components of the clinical guidelines develop-
ment process were separated: a clinical consensus process that
defined risk thresholds for surveillance intervals, colposcopy re-
ferral, and treatment. In parallel, risk estimates from screening
and triage tests and prior screening information were calculated
to assess a patient's risk of cervical precancer based on robust clin-
ical databases and published data.
Systematic reviews of diagnostic accuracy studies are an im-
portant component of evidence assessment for developing clinical
practice guidelines and can also demonstrate where current
knowledge gaps exist to guide future research. The strength of ev-
idence is largely dependent on the availability of high-quality
studies that can be synthesized by meta-analyses to ensure gener-
alizability and support recommendations.1–3 Cervical cancer pre-
vention is based on a multistep process involving population
screening and management of screen-positive individuals to
decide who needs treatment.4 Consequently, the performance
evaluation of tests for cervical cancer screening is context depen-
dent and underlying populations and study designs vary depend-
ing on which step of the screening and management process is
being evaluated. This context dependence of cervical cancer
screening and management can complicate the quality assessment
of diagnostic studies, because study designs and procedures for
various clinical management scenarios of screen-positive individ-
uals may differ from those designed to evaluate screening tests and
vice versa. For instance, one cannot extrapolate the use of a test
approved for screening to be equally as useful in posttreatment
surveillance. Therefore, using standardized, context-adapted
approaches to perform quality assessment is important to assure
high-quality evidence reviews that are clinically meaningful.
Several tools have been developed to assess and improve the
quality of diagnostic accuracy studies. The Standards for Reporting
Diagnostic Accuracy statement, designed to improve the quality of
reporting of diagnostic accuracy studies, is primarily targeted at re-
searchers who publish their findings.5 The Quality Assessment of
Diagnostic Accuracy Studies 2 (QUADAS-2) tool is used to evalu-
ate the risk of bias and applicability of diagnostic accuracy studies
in systematic reviews.6 These tools provide an important foundation
for researchers to design and assess high-quality studies, but they
are very general, andmany criteria unique to cervical cancer screen-
ing and management studies are not addressed by these tools.
The creators of the QUADAS-2 tool intended for their ge-
neric guidance to be adapted for specific questions or systematic
reviews.6 The field of cervical cancer screening and management,
with an ever-growing number of assays and a wide range of20 157
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quality criteria to improve the reliability, precision, and reproduc-
ibility of these criteria. As part of the 2019 ASCCP Risk-Based
Management Consensus Guidelines effort, the New Technologies
Working Group conducted a systematic review of the literature
evaluating assays for management of abnormal cervical cancer
screening results. In that context, a team of content experts
reviewed the QUADAS-2 criteria and adapted them for use with
studies of cervical cancer screening and management. This article
describes the adaptation process and the application of these stan-
dard methods to the systematic review. Beyond the application to
the current guidelines process, these criteria will support future
evidence reviews and provide guidance for researchers and re-
viewers to improve design and reporting of diagnostic accuracy
studies in the setting of cervical cancer screening and management.
METHODS
Adaptation of QUADAS-2 Criteria to Studies of
Cervical Cancer Screening and Management
The QUADAS-2 tool was developed to assess the quality of
diagnostic accuracy studies and is recommended for use in sys-
tematic reviews of diagnostic accuracy by the Agency for Health-
care Research and Quality, Cochrane Collaboration, the UK
National Institute for Health and Clinical Excellence, and among
others.6 The tool covers 4 domains including: (1) Patient selection,
(2) index test, (3) reference standard, and (4) flow and timing (i.e.,
the flow of patients through the study and timing of the index test
[s] and reference standard). Each domain includes signaling ques-
tions that are designed to help the reviewer(s) assess the risk of
bias and the first 3 domains are also assessed in terms of concerns
regarding applicability. We formally adapted the QUADAS-2
criteria for diagnostic accuracy studies in cervical cancer screen-
ing andmanagement. In support of the update of the 2019ASCCP
Risk-Based Management Consensus Guidelines, the New Tech-
nologies Working Group conducted systematic reviews of tests
for postcolposcopy and posttreatment surveillance. All working
group members participated in the assessment of study eligibility
and full-text abstraction of relevant articles (Clarke et al., in this
issue). During the abstraction process, working group members
evaluated the quality of all 5 postcolposcopy studies8–12 and 23
posttreatment studies13–35 included in the systematic reviews
using the generic QUADAS-2 criteria that uses 11 signaling ques-
tions across the 4 domains (Supplemental Table 1 http://links.lww.
com/LGT/A147).6 After this initial quality assessment, clinical
criteria and signaling questions were discussed among the work-
ing group and adapted to cervical cancer screening and manage-
ment questions, according to the guidance from QUADAS-2
(first adaptation, supplemental Table 1 http://links.lww.com/
LGT/A147). This process relied on having a diverse working
group with experts in different areas, including gynecology, pa-
thology, epidemiology, and assay evaluation that are all relevant
to different areas of the quality assessment. From the original
QUADAS-2 questions, Q2, Q5, andQ8were reworded. One ques-
tion eachwas added to the index test and reference test domains. Q10
was dropped from the flow and timing domain, because the content
was included in Q9. Subsequently, 2 authors (M.A.C. and N.W.)
applied the adapted criteria for quality assessment of a random
third of the articles (n = 7). Agreement between both observers
was evaluated and discrepant ratings were discussed and resolved.
This process identified that the domain of patient selection re-
quired further clarification. The signaling questions Q1 to Q3,
and the related explanations were updated accordingly (final ad-
aptation, supplemental Table 1 http://links.lww.com/LGT/A147).
In addition, some descriptions for signaling question in the flow158 © 2020 The Auand timing category were updated as well. The final adaption in-
cluded 3 signaling questions for each of the 4 domains. Five ques-
tions were kept unchanged from QUADAS-2 (Q4, Q7, Q9, Q11,
Q12), 5 were adapted (Q1, Q2, Q3, Q5, Q10), and 2 were newly
developed (Q6, Q8). Subsequently, 2 authors (M.A.C. and N.W.)
evaluated 10 articles and achieved high agreement on the quality
assessment. Consensus ratings were recorded for all studies that
were evaluated by 2 observers. The remaining articles were
divided between the 2 authors and underwent quality assessment
using the final adapted criteria outlined hereinafter.
Study Quality Assessment and Statistical Analysis
Each study was assessed using 12 signaling questions
(3 from each domain) and 3 questions regarding study applicabil-
ity (1 each from the first 3 domains). The rating for each question
is yes/no/unclear. “Yes” indicates a small risk of bias, whereas
“no” indicates a high risk of bias for the specific question.
“Unclear” indicates that the risk of bias could not be assessed be-
cause of missing information. We assessed agreement between
both evaluators using 3 (yes/no/unclear) and 2 (yes or combined
unclear/no) response levels. Agreement was calculated for each
question, for each domain, and for the overall assessment.
Studies that were judged as “low” on all domains regarding
bias or applicability were rated as having an overall low risk of bias
or low concern regarding applicability. Studies that were judged as
having high risk of bias in 1 or more domains were rated as having
an overall high risk of bias or high concern regarding applicability.
To demonstrate the impact of quality ratings on test perfor-
mance, we conducted subgroup meta-analyses to evaluate differ-
ences in the overall baseline risk of cervical intraepithelial
neoplasia grade 2 or worse (CIN) 2+, the risks in test positives
and test negatives, and between study variance quantified using
the τ2 statistic36,37 in the subset of studies evaluating human pap-
illomavirus (HPV) tests for posttreatment (n = 21) according to
study quality. For these analyses, we evaluated the effects of having
any risk of bias (1 or more domains ranked as high risk) and having
2 or more domains ranked as high risk. We also evaluated the ef-
fects of risk of bias and concerns about applicability for each
domain. Where feasible, we assessed the influence of domain-
specific signaling questions that had demonstrated variability in re-
sponses (Q2, Q3, Q6, andQ11). Statistical analyseswere conducted
in Stata SE Version 15 using the metaprop_one package.37
Role of the Funding Source
The guidelines effort received support from the National
Cancer Institute and ASCCP. Participating organizations sup-
ported travel for their participating representatives. All participat-
ing consensus organizations, including the primary funders, had
equal and balanced roles in the consensus process including data
analysis and interpretation, writing of manuscript, and decision
to submit for publication. No industry funds were used in the
development of these guidelines. The corresponding authors had
final responsibility for the submission decision.RESULTS
Interobserver Agreement of Adapted
Quality Assessment
For a first set of 7 studies, we evaluated the interrater agree-
ment between both observers as an initial assessment of the
adapted signaling questions. Across all 7 studies, the percent
agreement was 70.2% when comparing individual responses of
“yes” versus “unclear” versus “no” and 76.2% when comparing
responses of “yes” versus “unclear/no.” For individual signalingthor(s). Published by Wolters Kluwer Health, Inc. on behalf of the ASCCP.
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100.0% (Q1, Q2, Q4, and Q7) when comparing individual re-
sponses. Based on these results, questions 1 and 2 were combined
because these were interdependent and nondiscriminatory as
standalone questions. To evaluate the adapted QUADAS-2
criteria, we compared quality assessment of 10 articles from a sys-
tematic review of posttreatment surveillance between 2 observers.
Two reviewers independently assessed the criteria (see Table 2).
The agreement using the revised signaling questions and clarifica-
tions increased to 83% for individual responses and to 87% for
“yes” versus “unclear/no.” For the first set of 7 studies, agreement
for applicability ratings ranged from 57% for patient selection,
86% for index test, and 100% for reference standard. For the sec-
ond set of 10 studies, agreement improved to 90% for patient selec-
tion and index test and 100% for reference standard.
The components of the quality assessment are summarized in
Figure 1. The assessment domains include patient selection, index
test, reference standard, and flow and timing. In the following sec-
tions, each domain and signaling questions are described within
the context of cervical cancer screening and management studies.
Domain: Patient Selection
The patient selection domain addresses the question: “Could
the selection of patients or study participants have introduced
bias?” The constitution of the study population is centrally impor-
tant to a high-quality study.We distinguished 3 populations, study,
source, and target. The study population is the population that is
reported on in an article, sampled from a larger source population.
The target population is the group for whom study results are sup-
posed to inform (see Figure 1). The bias assessment evaluates dif-
ferences between the study population and the source population,
whereas the applicability question evaluates whether findings
from the study population will apply to the target population.
Signaling Question 1: Was a Consecutive or Random
Sample of Patients Enrolled? If Sampling Was Performed,
Was the Sampling Frame Adequately Described?. The study
population should be representative of the underlying source
population. Enrolling a consecutive series of a large number of
patients can ensure a representative sample, unless there are
specific variations over time, like changes in screening or clinical
practice, that would alter the constitution of the source population.FIGURE 1. Components of quality assessment for diagnostic accuracy st
reference standard, and flow and timing. The patient selection domain a
included in the study (i.e., the study population). The study population
eligible based on study inclusion criteria). The target population is the exte
test domain addresses potential sources of bias for the assay/test under inv
of positive or negative index test results. The reference standard domain
measurement of study outcomes. A simple schematic shows possible ou
Together, the results from the index test and reference standard can be i
index test. Flow and timing addresses potential sources of bias in the flo
© 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of tA random sample taken from the source population for an
extended period can also yield a study population that is
representative of the source population. Study designs that
enrich for individuals at higher risk of precancer can be very
efficient, particularly for studies of cervical cancer screening
and triage. However, it is critical that the enriched population
is weighted back to the source population for the purpose of
reporting of accuracy and risk estimates. Successful weighting
requires unbiased sampling of cases and controls, as well as
knowledge of the sampling frame.
Signaling Question 2: Did the Study Avoid Inappropriate
Exclusions?. All exclusions made when creating the study
population from the source population need to be documented
and described. Exclusions should be prespecified and should not
be related to specific index test or reference test results.
Exclusions are considered inappropriate if they alter the study
population in such a way that potentially introduces bias and/or
does not address the intended research question. Examples of
inappropriate exclusions that are likely to introduce bias include:
excluding unsatisfactory index test results or exclusions based
on a specific screening result.
Signaling Question 3: Did the Study Avoid Exclusion of a
Substantial Number From the Source Population Due to
Missing Data?. When patients are included from routine
clinical practice or electronic medical records, important data
needed for study inclusion may be missing in eligible participants.
Any exclusions need to be clearly described and enumerated. If
the data are missing at random, risk of bias should be low. As
the reasons for missing information cannot be sufficiently
evaluated, large proportions (>15–20%) of missing data may
introduce bias. Examples that may introduce bias if the proportion
of missing data is substantial include missing index test results
and patients lost to follow-up.
Applicability: Are There Concerns That the Included
Patients Do Not Match the Research Question?. This
question addresses whether the findings from the study population
will be applicable to the target population. Applicability may be
affected when the age range and age distribution of the studyudies. The assessment domains include patient selection, index test,
ddresses potential sources of bias in the selection of patients
is sampled from a larger source population (the population that is
rnal population towhich results are intended to inform. The index
estigation in the study. A simple schematic shows possible outcomes
addresses potential sources of bias in the ascertainment and/or
tcomes of positive or negative results for the reference standard.
ncluded in a 2  2 table to evaluate the diagnostic accuracy of an
w and timing of procedures carried out in the study.
he ASCCP. 159
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when the extent of previous screening and management is not
comparable with the target population, and/or if the study is
restricted to individuals with certain screening results. In addition,
there are other population characteristics that may influence the risk
of disease, for example, HIV prevalence or immunosuppression,
which may introduce concerns about applicability if the intended
target is the general population.
Considerations for Specific Indications
For screening and triage, the source population should reflect
individuals undergoing routine cervical cancer screening in the
appropriate age range (e.g., 21–65 years), and the study popula-
tion should include a series of consecutively screened patients or
a random sample that can be weighted back to the full screening
population. If the population is enriched for disease endpoints
(e.g., from a colposcopy referral population), then a sampling
frame and weighting scheme should be described that allows ex-
trapolation back to the full screening population. Importantly,
when colposcopy clinics are used for enrichment, use of referral
criteria that differ from the study question risks the introduction
of bias (e.g., if the colposcopy population is based on cytology
screening, but the study is evaluating HPV screening). A screening
population should include individuals without prior screening ab-
normalities because previous test results are an important indica-
tor of risk. If the screening history of patients is not known, this
should be specifically stated. For postcolposcopy surveillance,
the source population is individuals who have undergone colpos-
copy without treatment; including those with CIN 2 or less. The
study population should include a series of consecutive patients
with previous colposcopy within 6 to 18months. Previous screen-
ing methods and postcolposcopy management algorithms should
be clearly described (e.g., cytology-based screening vs co-testing).
For posttreatment surveillance, the source population should reflect
individuals who have undergone excisional treatment for histologi-
cally confirmed CIN 2, CIN 3, or adenocarcinoma in situ and should
not include patients treated for cervical cancer, as well as no or few
(≤10%) treated less than CIN 2. The study population should include
a series of consecutive patients with previous treatment in the last 6 to
18 months, and the treatment modality should be described.
Domain: Index Test
The index test domain addresses the question: “Could the
conduct or interpretation of the index test have introduced bias?”
The index test results are one central component of a 2  2 table
that is evaluated in diagnostic studies (see Figure 1). The index test
is the assay under investigation in the study, and a study may eval-
uate 1 or more index tests in the same population or among pop-
ulation subsets. The study methods should provide a clear
description of the index test, how it was conducted, and how it
was and interpreted. Index tests that are currently used in clinical
practice for cervical cancer screening and management include
cervical cytology and HPV testing (including HPV DNA and
mRNA testing). Current candidate diagnostic tests for cervical
cancer screening and management include technologies such as
extended HPV genotyping,38 p16/Ki-67 dual stain,39–42 cellular
and viral DNA methylation,43–47 and automated visual evaluation.48
Signaling Question 4: Were the Index Test Results
Interpreted Without Knowledge of the Results of the
Reference Standard?. In clinical practice, cervical cancer
screening tests and management (e.g., cytology or HPV testing) are
conducted before performing the reference standard (colposcopy
and biopsy) being performed. Therefore, if the index test is being
conducted as part of routine clinical practice, it is reasonable to160 © 2020 The Auassume that it was interpreted without knowledge of the reference
test results, even if this is not explicitly stated in the Methods. In
studies that use previously collected, banked samples to evaluate an
index test that was not part of routine clinical care, results of the
candidate index test should be interpreted without knowledge of
the results from the reference standard. The Methods should
clearly state that reference standard results were not known to
those interpreting the index tests under evaluation.
Signaling Question 5: Was the Threshold for the Index
Test Prespecified?. It is presumed that all index tests used in
cervical cancer screening have a threshold; therefore, a description
of the prespecified threshold (i.e., test positivity cutoffs or result
categories of the index test) should be clearly stated in the
methods section. If the index test is a commercially available kit,
it is sufficient to state that it was carried out according to routine
practice and/or the manufacturer's instructions with the appropriate
references included.
Signaling Question 6: Were Patients With Inadequate,
Indeterminate, or Missing Index Test Results Reported?.
Exclusion of patients in the study population with inadequate,
indeterminate, or missing index test results may introduce bias.
Therefore, these results should be enumerated in the Methods or
Results section and ideally reported with results from the
reference standard to assess the risk of disease in these patients.
Applicability: Are There Concerns That the Index Test,
Its Conduct, or Its Interpretation Differ From the
Research Question?. Factors that may affect the diagnostic
accuracy results of the index test, and therefore the applicability
of study findings, include variations in test technology (e.g.,
manual vs automated cytology or dual stain testing, sampling
methods, assays used for high-risk HPV testing, and the number
of HPV types classified as “high-risk”), training and expertise of
those performing and evaluating the index test if expected setting
for use differs from the study (e.g., commercial laboratory vs a
clinical setting), and variation in sample storage times and
conditions (e.g., comparing results from freshly collected samples
or extracts to those stored or frozen before or after extraction).
Domain: Reference Standard
The reference standard domain addresses the question:
“Could the reference standard, its conduct, or its interpretation
have introduced bias?” The reference test results are the other cen-
tral component of the 2  2 table that is evaluated in diagnostic
studies, describing the study endpoints or outcomes (see Figure 1).
The study methods should provide a clear description of the
reference test, how it was conducted, and how it was interpreted.
The reference standard for cervical cancer screening and
management studies is based on histologic evaluation of cervical
biopsies and/or excisional treatment specimens. However, not all
patients have results for the reference test as they may not
undergo biopsy or excisional treatment. Depending on other
clinical characteristics (e.g., negative HPVand negative cytology
and/or normal colposcopic impression), these patients may be
considered as noncases in screening and management studies.
Signaling Question 7: Is the Reference Standard Likely to
Correctly Classify the Outcomes?. The reference standard in
cervical cancer screening and management studies is histologic
evaluation of biopsy specimens collected during colposcopy or
excisional treatment. This reference standard requires a combination
of high-quality colposcopy and histology.49 To obtain complete
disease ascertainment, colposcopy evaluation needs to be conductedthor(s). Published by Wolters Kluwer Health, Inc. on behalf of the ASCCP.
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acetowhite lesions. Similarly, histologic evaluation requires high
standards and interpretation should follow established nomenclature
and diagnostic criteria. When using the lower anogenital squamous
terminology (LAST) nomenclature,50 the use of p16 or other
immunohistochemical assays in diagnostic framework should
follow guidelines systematically and be clearly described.
Signaling Question 8: Are the Distributions of CIN 2,
CIN 3, and Cancer Endpoints Reflective of the Case
Mix That Would Be Encountered in Clinical Practice?.
A study that is skewed toward having too little or too few CIN 3
endpoints, for example, may signal a risk of bias in the conduct
and interpretation of the reference standard. At a minimum, CIN
3 should be enumerated separately from CIN 2 outcomes in the
results section so that readers can determine the distribution
of these two endpoints. Cancers are typically very rare in
screening and management studies. Ideally, primary endpoints for
diagnostic accuracy should include CIN 3+, with CIN 2+ reported
separately. If LAST criteria are used, it is important to report high-
grade squamous intraepithelial lesion results as qualified by –CIN 2
or –CIN 3, according to the options given by the LAST guidelines.50
Signaling Question 9: Was the Interpretation of the
Reference Test Carried Out Without Being Influenced
by the Specific Results of the Index Test?. Typically, the
reference test should be interpreted independent of results of
the index test. However, in cervical cancer screening and
management, clinical algorithms may reveal some index test results
(e.g., when HPV-positive individuals are referred to colposcopy).
Furthermore, pathology practice may include evaluating the
complete clinical picture when histologic assessment occurs, i.e., all
screening test results are revealed to the pathologist and the
pathologist may review prior cytology or histology slides. This
practice may vary in different settings (e.g., academic teaching
centers versus commercial diagnostic laboratory) as well as
between individual pathologists and cannot be controlled in studies
that rely on clinical databases. Detailed reporting of pathology
practice is important to assess the risk of bias in these situations.
Applicability: Are There Concerns That the Reference
Standard, Its Conduct, or Its Interpretation Differ From
the Research Question?. Current risk-based screening and
management guidelines are based on CIN 3+ endpoints; therefore,
studies reporting only CIN 2+ may be difficult to extrapolate to risk
estimates used for clinical decision-making. Furthermore, the
constitution of the group of endpoints can affect the applicability of
the study findings. For example, the number of cancers included in
CIN 3+ endpoints can vary substantially between studies and may
affect risk estimates for various tests.
Domain: Flow and Timing
The flow and timing domain addresses the question: “Could
the study flow and timing have introduced bias?” The Methods
and Results sections should provide a clear description of clinical
referral algorithms (i.e., patients who did/did not receive the index
tests or reference standard, respectively) and of any patients ex-
cluded from the analyses. The follow-up time interval and any in-
terventions between the index test(s) and the reference standard
should also be clearly described.
Signaling Question 10: Was the Time Interval Between
Sample Collection for Testing and Application of the
Reference Standard Acceptable and Similar to What
Would Be Done in Clinical Practice?. The time interval© 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of tbetween sample collection for index testing and the application
of the reference standard should reflect what is done in routine
clinical practice (see considerations for specific indications
hereinafter). At a minimum, the results should report summary
measures of follow-up time for all participants (e.g., mean/
median with standard deviations and/or ranges). If the interval is
outside of the range of what is considered normal by routine
clinical standards for a given indication, this could introduce
bias. Ideally, a description of the clinical referral algorithm
should be provided so that the timing of index testing and
application of the reference standard can be assessed by reviewers.
Signaling Question 11: Did All Patients Receive the
Reference Standard?. Generally, in diagnostic studies, it is
expected that all study participants receive a reference standard.
However, because HPV-negative women in the general
population have a very low risk of cervical precancer, and most
a general population is negative for HPV, the reference standard
is typically not applied to the whole population in cervical
cancer screening studies. Referring all individuals with negative
screening tests to colposcopy would be an extensive and
unnecessary burden. For management indications, the tradeoff
between complete disease ascertainment and unnecessary referral
is altered and the requirements may be different, as outlined
hereinafter. When the reference standard of colposcopy and
biopsy is not applied to all patients, there needs to be a clear
description of what approach was used to determine disease
endpoints (see considerations for specific indications hereinafter).
Importantly, the referral algorithm should not introduce bias.
When evaluating an index test, unbiased comparisons require
colposcopy referral at some point for all patients testing positive.
When evaluating multiple index tests, all individuals testing
positive for any test should be referred to colposcopy equally.
In some studies, patients whowere supposed to receive a ref-
erence standard may be lost to follow-up. This can introduce bias
when the risk in the patients who did not undergo the reference
standard differs from the risks in patients who do. The degree to
which this may introduce bias is increased as the proportion of in-
dividuals who are lost to follow-up increases (captured in Q3 in
the patient selection domain).
Signaling Question 12: Were All Enrolled Study Patients
Included in the Analysis?. There is potential for bias if the
number of patients enrolled differs from the number of patients
included in the 2  2 table analysis and results. Some patients
may not be included in the analysis because of missing results
of 1 or more tests. Such differences should be clearly stated or
described in a Consolidated Standards of Reporting Trials diagram.
Considerations for Specific Indications
For screening and triage, different study designs exist. Clini-
cal or registration trials typically refer all individuals positive for
any test to colposcopy immediately and conduct follow-up for at
least 3 years. For studies integrated in clinical practice, referral al-
gorithms and times may differ depending on screening test results.
Therefore, the reference standard may not be equally applied to
the whole population. For example, in a co-testing setting, patients
who are HPV positive with atypical squamous cell of undeter-
mined significance or worse undergo immediate colposcopy,
whereas patients who are HPV+ with negative for intraepithelial
lesions or malignancy may return for repeat testing in 1 year. Sim-
ilarly, individuals with negative cytology and negative HPV results
do not need to undergo colposcopy, and biopsies are not taken. If
their screening results are negative, it is acceptable to assume no
precancer or cancer in these individuals. Verification bias adjustmenthe ASCCP. 161
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Clarke et al. Journal of Lower Genital Tract Disease • Volume 24, Number 2, April 2020has been proposed to account for the lack of histologic endpoints in
individuals with negative screening results. Verification bias ad-
justment involves conducting tests for the reference standard
(colposcopy/biopsy and histology) in a subset of individuals with
negative screening results, followed by weighting back to the full
population. However, the risk of precancer is very low in screen-
negative individuals, and there is a risk of detecting morphologic
look-alike lesions that are not caused by carcinogenic HPV and
are not true precancers, leading to incorrect adjustments of
precancer prevalence. In postcolposcopy studies, similar arguments
can be made and it is not required that all women are sent to colpos-
copy if the tests used for management provide sufficient reassur-
ance against disease. For posttreatment studies, it is expected
that individuals are evaluated with colposcopy at some point dur-
ing follow-up. Because the size of the population is relatively
small, and the baseline risk is higher compared with a screening
population, unnecessary colposcopy is much less of a concern.
Quality Assessment of Studies Included in
Systematic Review of Postcolposcopy and
Posttreatment Management
Consensus ratings for the 5 postcolposcopy surveillance
studies and the 23 posttreatment studies included in the systematic
review are shown in Tables 1 and 2, respectively. Overall, studies
tended to be of low quality, with all 5 of the postcolposcopy stud-
ies having at least one domain rated as high risk of bias and 21
(91%) of the posttreatment studies having at least one domain
with a high risk of bias. All 5 postcolposcopy studies and 12 of
the posttreatment studies (52%) were rated as having high risk
of bias in at least 2 domains.
Evaluation of domain-specific results for the 23 posttreat-
ment articles demonstrated variability with respect to overall
domain ratings as well as responses to individual signaling ques-
tions. For example, only 3 studies (13%) were rated as having a
low risk of bias for the patient selection domain. Studies were
more likely to be considered as having a low risk of bias for the
index test and reference standard domains (n = 12, 52%, respec-
tively) and the flow and timing domain (n = 9, 39%). Within do-
mains, ratings varied substantially by signaling question. For
example, within the patient selection domain, only one study
(5%) was judged as having high risk of bias for Q1, whereas for
Q2 and Q3, those numbers increased to 9 (43%) and 13 (62%), re-
spectively. This demonstrates that inappropriate exclusions and
exclusions of a high percentage from the base population are com-
mon in the literature. Very few studies were judged as high risk of
bias for index test domain signaling questions Q4 (n = 0) and Q5
(n = 1, 5%), reference standard domain signaling questions Q7
(n = 1, 5%) and Q9 (n = 0, 0%), and flow and timing signaling
questions Q10 (n = 0, 0%) and Q12 (n = 1, 5%), whereas Q8 (ref-
erence standard) and Q11 (flow and timing) had more studies
judged as high risk of bias (n = 11 [52%] and n = 9 [43%], respec-
tively). Concerns about applicability were observed in 7 (33%)
studies for the patient selection, 6 (29%) studies for the index test,
and 3 (14%) studies for the reference standard domains. A total of
5 (24%) posttreatment studies had concerns about applicability in
more than one domain.
Influence of Study Quality on Between-Study
Variance and Risk Estimates
To demonstrate how study quality assessment may influence
performance estimates reported in the systematic review, we per-
formed analyses of the baseline and posttest risks as well as τ2 es-
timates of between study variation, stratified by different measures
of study quality (see Table 3). Overall for studies with 2 or more
domains with high risk of bias, the risk estimates were not162 © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the ASCCP.
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Clarke et al. Journal of Lower Genital Tract Disease • Volume 24, Number 2, April 2020statistically significantly different than those studies with one or
fewer domains having high risk of bias (p value for heterogeneity
>0.1 for all comparisons). Among studies with low risk of bias
overall and for each domain, τ2 estimates tended to be lower than
those with high risk of bias and compared with the overall τ2 esti-
mates (see Table 3). Bias within individual domains had different
effects on baseline and posttest risk estimates, but these differ-
ences were not statistically significant.
For applicability measures, we observed differences in the
baseline and posttest risk estimates, but these differences were
not statistically significant. Among studies with low concerns
about applicability for each domain, τ2 estimates tended to be
lower than those with high concerns, with the exception of the ref-
erence standard domain.DISCUSSION
A thorough assessment of the quality of diagnostic accuracy
studies included in systematic reviews and meta-analyses is essen-
tial for interpreting the strength and robustness of evidence used
for clinical decision-making in cervical cancer screening andman-
agement.6 Issues with the design, conduct, or reporting of diag-
nostic accuracy studies can potentially lead to bias and/or results
that are not applicable to the research question of interest. To
assess the quality of diagnostic accuracy studies included in
the systematic review for the 2019 ASCCP Risk-Based Man-
agement Consensus Guidelines, we adapted a widely used toolTABLE 3. The Influence of Study Quality on CIN 2+ Risk Estimates
HPV Tests (n = 21)
n Baseline risk τ2 R
Risk of bias
<2 domains 12 0.049 (0.034–0.069) 0.2788 0.
≥2 domains 9 0.048 (0.025–0.090) 0.9374 0.
Patient selection
Low 3 0.066 (0.033–0.126) 0.3055 0.
High 13 0.048 (0.030–0.075) 0.6684 0.
Unclear 5 0.049 (0.026–0.092) 0.4772 0.
Index test
Low 11 0.040 (0.024–0.066) 0.6689 0.
High 6 0.066 (0.039–0.108) 0.3959 0.
Unclear 4 0.062 (0.033–0.114) 0.3383 0.
Reference standard
Low 12 0.055 (0.037–0.081) 0.3835 0.
High 9 0.042 (0.023–0.074) 0.7624 0.
Unclear 0
Flow and timing
Low 8 0.039 (0.021–0.072) 0.7424 0.
High 8 0.063 (0.039–0.101) 0.4361 0.
Unclear 5 0.054 (0.031–0.094) 0.3160 0.
Applicability
Patient selection
Low concern 14 0.054 (0.040–0.073) 0.2481 0.
High concern 7 0.040 (0.018–0.088) 1.1370 0.
Index test
Low concern 15 0.055 (0.041–0.074) 0.2664 0.
High concern 6 0.038 (0.016–0.088) 1.1711 0.
Reference standard
Low concern 19 0.047 (0.032–0.070) 0.6221 0.
High concern 2 0.057 (0.041–0.079) 0.0000 0.
164 © 2020 The Aufor evaluating the quality of diagnostic accuracy studies, the
QUADAS-2,6 for studies of cervical cancer screening and man-
agement. Our adapted tool provides specific guidance for how
to evaluate the risk of bias and applicability of studies in the
context of the various cervical cancer screening and management
settings (screening and triage, postcolposcopy surveillance, and
posttreatment). In a meta-analysis of risk estimates, 2 factors are
important: the actual risk estimate and the CI around the risk esti-
mate (i.e., precision). Both factors can be affected in biased stud-
ies. If studies are all judged to have the same risk of bias that acts
toward a specific direction (e.g., higher risk), the bias should have
a predictable effect on the overall risk estimate within this sub-
group (higher risk compared with studies without this bias). How-
ever, if the bias affects the risk estimate unpredictably in both
directions, the subgroup-specific risk estimate may not be differ-
ent from the overall risk estimate, but the precision could be lower,
and the between-study variation will be higher. In context of the
guidelines, it is important how close a risk estimate is in relation
to a clinical management threshold. If the risk is very close to
the threshold, the precision of the risk estimate from a systematic
review and meta-analysis becomes more important than if the risk
is very different from the threshold (Cheung et al., in this issue).
The iterative process we applied for adapting the QUADAS-2
tool resulted in high interobserver agreement for evaluating risk of
bias and concerns about study applicability in studies evaluating as-
says for postcolposcopy and posttreatmentmanagement. Importantly,
we identified a high risk of bias in at least one domain for mostand Between Study Variation, Posttreatment Studies Evaluating
isk in negatives τ2 Risk in positives τ2
006 (0.002–0.018) 1.5406 0.161 (0.100–0.251) 0.7259
008 (0.003–0.023) 1.9964 0.211 (0.106–0.378) 1.3994
009 (0.002–0.050) 0.9790 0.217 (0.124–0.353) 0.2276
008 (0.003–0.018) 1.7193 0.163 (0.057–0.390) 1.0943
008 (0.001–0.051) 2.9129 0.204 (0.122–0.321) 1.6534
007 (0.003–0.016) 1.3692 0.181 (0.105–0.295) 0.9741
005 (0.001–0.031) 3.7472 0.217 (0.112–0.377) 0.8518
029 (0.016–0.053) 0.000 0.195 (0.055–0.503) 1.9348
005 (0.001–0.022) 3.0756 0.170 (0.098–0.279) 1.0322
008 (0.004–0.018) 1.0164 0.200 (0.106–0.345) 1.0872
005 (0.001–0.014) 1.4547 0.193 (0.096–0.350) 1.2500
010 (0.003–0.031) 2.0888 0.233 (0.141–0.359) 0.6170
016 (0.005–0.049) 0.4756 0.143 (0.051–0.343) 1.5296
009 (0.004–0.021) 1.6770 0.189 (0.129–0.268) 0.5613
004 (0.001–0.016) 1.5184 0.177 (0.067–0.392) 2.0179
010 (0.005–0.022) 1.3716 0.175 (0.112–0.263) 0.8379
003 (0.001–0.014) 1.9617 0.206 (0.082–0.429) 1.5688
007 (0.003–0.016) 2.2601 0.177 (0.112–0.268) 1.1648
009 (0.003–0.023) 0.000 0.208 (0.150–0.281) 0.1161
thor(s). Published by Wolters Kluwer Health, Inc. on behalf of the ASCCP.
Journal of Lower Genital Tract Disease • Volume 24, Number 2, April 2020 Quality Assessment of Evidencestudies included in our systematic review. The patient selection and
flow and timing domains were most likely to have a high risk of bias
for at least one of the signaling questions, reflecting the wide var-
iation in clinical practice and the lack of standards for conducting
postcolposcopy and posttreatment studies. Using these adapted
criteria, we demonstrated that meta-analyses of studies with lower
risk of bias and concern about applicability generally have less
between-study variation, producing more robust and precise risk
estimates. Conversely, we did not observe statistically significant
differences in the absolute risk measures in studies with high ver-
sus low risk of bias, suggesting that the potential biases do not
affect risk estimates in a specific direction, and that the point esti-
mates reflect the actual risks from the source population. It is im-
portant to point out that bias in certain domains and for certain
signaling questions could have differential impact on the resulting
risk estimates, and it is challenging to predict in which direction
the bias will act. Even where we observed nonstatistically signif-
icant differences in risk estimates, these differences generally
did not cross a risk threshold, with few marginal exceptions.
Our study was limited by the relatively few primary stud-
ies that were eligible for inclusion for the quality assessment. In
the future, we will validate this tool using additional studies for
other indications (e.g., triage of HPV-positive individuals), which
will allow for greater power to detect associations between study
quality and risk estimates and may enable a more detailed assess-
ment of specific signaling questions and further adaptation of
this tool.
Although use of the adapted QUADAS-2 was tightly linked
to the systematic review for the ASCCP guidelines effort, this tool
will have broad application for researchers, evidence evaluators,
and journals who are interested in designing, conducting, evaluat-
ing, and publishing studies for cervical cancer screening and man-
agement. Going forward, these criteria will serve a dual purpose
for evaluating the quality of evidence, as well as supporting and
improving future planning and reporting of studies.REFERENCES
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